Applications of new technology in molecular epidemiology and their relevance to occupational medicine

Occupational and Environmental Medicine

Volumn 56, Issue 11, 1999, Pages 725-729

  Koh, David ^a   Seow, Adeline ^a   Ong, Choon Nam ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Biologically effective dose; Biomarkers; Early response markers; Genetic polymorphisms; Internal dose; Molecular epidemiology

Indexed keywords

BIOLOGICAL MARKER;

BIOCHEMISTRY; ENVIRONMENTAL DISEASE; ENVIRONMENTAL HEALTH; ENVIRONMENTAL MONITORING; GENETIC EPIDEMIOLOGY; GENETIC POLYMORPHISM; GENETIC SCREENING; HUMAN; MEDICAL ETHICS; METABOLISM; MOLECULAR BIOLOGY; OCCUPATIONAL MEDICINE; PRIORITY JOURNAL; PRIVACY; RISK ASSESSMENT; SHORT SURVEY; WORK ENVIRONMENT;

EID: 0032830058     PISSN: 13510711     EISSN: None     Source Type: Journal    
DOI: 10.1136/oem.56.11.725     Document Type: Short Survey

References (49)

1. Perera FP, Weinstein IB. Molecular epidemiology and carcinogen-DNA adduct detection: new approaches to studies of human cancer causation. J Chron Dis 1982;35:581-600.
2. Hulka BS. Overview of biological markers. In: Hulka BS, Wilcosky TC, Griffith JE, eds. Biological markers in epidemiology. New York: Oxford Univ Press, 1990:3-15.
3. Perera F, Santella R, Piorier M. Biomonitoring of workers exposed to carcinogens: immunoassays to benzo(a)pyrenc-DNA adducts as a prototype. J Occup Med 1986;28:1117-23.
4. Schulte PA. Contribution of biological markers to occupational health. Am J Ind Med 1991;20:435-46.
5. McMichael AJ. Invited commentary: molecular epidemiology: new pathway or new travelling companion? Am J Epidemiol 1994;140:1-11.
6. Groopman JD, Kensler TW. The light at the end of the tunnel for chemical-specific biomarkers: daylight or headlight? Carcinogenesis. 1999;20:1-11.
7. Soderkvist P, Axelson O. On the use of molecular biology data in occupational and environmental epidemiology. J Occup Environ Med 1995;37:84-90.
8. Samet JM, Schnatter R, Gibb H. Epidemiology and risk assessment. Am J Epidemiol 1998;10:929-36.
9. Perera F. Uncovering new clues to cancer risk. Sci Am 1996;275:40-6.
10. Perera FP; Dickey C. Molecular epidemiology and occupational health. Ann N Y Acad Sci 1997;837:353-9.
11. Kuljukka T, Vaaranrinta R, Mutanen P, et al. Assessment of occupational exposure to PAHs in an Estonian coke oven plant: correlation of total external exposure to internal dose measured as 1-hydroxypyrene concentration. Biomarkers 1997;2:87-94.
12. Wilson VL, Weston A, Manchester DK, et al. Alkyl and aryl carcinogen adducts detected in human peripheral lung. Carcinogenesis 1989;10:2149-53.
13. Santella R, Hemminki K, Tang D, et al. PAH-DNA adducts in white blood cells and urinary 1-hydroxypyrene in foundry workers. Cancer Epidemiol Biomarkers Prev 1993;2:59-62.
14. Shi CY, Scow A, Lin Y, et al. Biomarkers: a molecular approach to cancer epidemiology. Ann Acad Med Singapore 1996;25:49-54.
15. Dubois M, Grosse Y, Thome JP, et al. Metabolic activation and DNA-adducts detection as biomarkers of chlorinated pesticide exposures. Biomarkers 1997;2:17-24.
16. McClure GYH, Freeman JP, Lay JO, et al. Haemoglobin adducts as biomarkers of exposure to the herbicides, propanil and fluometuron. Biomarkers 1996;1:136-40.
17. Brandt-Rauf PW. Oncogene proteins as biomarkers in the molecular epidemiology of occupational carcinogenesis. The example of the ras oncogene-encoded p21 protein. Int Arch Occup Environ Health 1991;63:1-8.
18. Luo JCJ, Lu HT, Cheng TJ, et al. Plasma Asp13-Ki-ras oncoprotein expression in vinyl chloride monomer workers in Taiwan. J Occup Environ Med 1998;40:1053-8.
19. Brandt-Rauf PW, Smotj S, Perera FP, et al. Serum oncogene proteins in foundry workers. Journal of the Society of Occupational Medicine 1990;40:11-4.
20. Brandt-Rauf PW, Smith S, Niman HL, et al. Serum oncogene proteins in hazardous waste workers. J Soc Occup Med 1989;39:141-3.
21. Ford J, Smith S, Luo JC, et al. Serum growth factors and oncoproteins in firefighters. Occup Med 1992;42:39-42.
22. Harris CC. p53: At the crossroads of molecular carcinogenesis and risk assessment. Science 1993;262:1980-1.
23. Esteve A, Sorlie T, Martel-Planche G, et al. Screening for p53 gene mutations in archived tumors of workers occupationally exposed to carcinogens: examples from analysis of bladder tumors. J Occup Environ Med 1995;37:59-68.
24. Smith SJ, Li YL, Whitley R, et al. Molecular epidemiology of p53 protein mutations in workers exposed to vinyl chloride. Am J Epidemiol 1998;147:302-8.
25. Husgafvel-Pursiainen K, Ridanpaa M, Anttila S, et al. p53 And ras gene mutations in lung cancer: implications for smoking and occupational exposures. J Occup Environ Med 1995;37:69-76.
26. Shi CY, Phang TW, Lin Y, et al. Codon 249 mutation of the p53 gene is a rare event in hepatocellular carcinomas from ethnic Chinese in Singapore. Br J Cancer 1995;72:146-9.
27. Shen HM, Ong CN. Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat Res 1996;366:23-44.
28. Rannug A, Alexandrie AK, Persson I, et al. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance. J Occup Environ Med 1995;37:25-36.
29. Garte S. The role of ethnicity in cancer susceptibility gene polymorphisms: the example of CYP1A1. Carcinogenesis 1998;19:1329-32.
30. Hayashi S, Watanabe J, Kawahri K. High susceptibility to lung cancer analysed in terms of combined genotype of P4501A1 and Mu-class glutathione S-transferase genes. Jpn J Cancer Res 1992;83:866-70.
31. Menegon A, Board PG, Blackburn AC, et al. Parkison's disease, pesticides, and glutathione transferase polymorphisms. Lancet 1998;352:1344-6.
32. Ishibe N, Kelsey KT. Genetic susceptibility to environmental and occupational cancers. Cancer Causes Control 1997;8:504-13.
33. Yu MC, Skipper PL, Taghizadeh K, et al. Acetylator phenotype, aminophenyl-haemoglobin adduct levels, and bladder cancer risk in whites, black and Asian men in Los Angeles. J Natl Cancer Inst 1994;86:712-6.
34. Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 1988;948:37-66.
35. Vainio H. Molecular approaches in toxicology: change in perspective. J Occup Environ Med 1995;37:14-8.
36. Ross RK, Jones PA, Yu MC. Bladder cancer epidemiology and pathogenesis. Seminars in Oncology 1996;23:536-45.
37. Chia KS, Shi CY, Lee J, et al. Molecular epidemiology: issues in study design and statistical analysis. Ann Acad Med Singapore 1996 25:55-63.
38. Lyles CM, Sandler RS, Keku TO, et al. Reproducibility and variability of the rectal mucosal proliferation index using proliferating cell nuclear antigen immunohistochemistry. Cancer Epidemiol Biomarkers Prev 1994;3:51-6.
39. Vineis P. Sources of variation in biomarkers. In: Toniolo P, Boffetta P, Shuker DEG, et al, eds. Application of biomarkers in cancer epidemiology. Lyon: International Agency for Research on Cancer, 1997:59-71. (IARC Sci Publ No 142.)
40. Gompertz D. Quality control of biomarker measurement in epidemiology. In: Toniolo P, Boffetta P, Shuker DEG, et al, eds. Application of biomakers in cancer epidemiology. Lyon: International Agency for Research on Cancer, 1997:215-22. (IARC Sci Publ No 142.)
41. VanRooij JGM, Bodelier-Bade MM, Jongeneelen FJ. Estimation of individual dermal and respiratory uptake of polycyclic aromatic hydrocarbons in 12 coke oven workers. Br J Ind Med 1993;50:623-32.
42. Hemminki K, Dickey C, Karlsson S, et al. Aromatic DNA adducts in foundry workers in relation to exposure, lifestyle and CYP1A1 and glutathione transferase M1 genotype. Carcinogenesis 1997;18:345-50.
43. Vineis P, McMichael AJ. Bias and confounding in molecular epidemiological studies: special considerations. Carcinogenesis 1998;19:2063-7.
44. Comings DE, Gade R, Wu S, et al. Studies of the potential role of the dopamine D1 receptor gene in addictive behaviours. Mol Psychiatry 1997;2:44-56.
45. Shields PG, Lerman C, Audrain J, et al. Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 1998;7:453-8.
46. Barrett JC, Vainio H, Peakall D, et al. 12th Meeting of the Scientific Group on Methodologies for the Safety Evaluation of Chemicals: susceptibility to environmental hazards. Environ Health Perspect 1997;105:699-737.
47. Koh D, Jeyaratnam J. Biomarkers, screening, and ethics. Occup Med (Oxf) 1998;48:27-30.
48. Pan G, Hanaoka T, Yamano Y, et al. A study of multiple biomarkers in coke oven workers: a cross-sectional study in China. Carcinogenesis 1998;19:1963-8.
49. Peluso M, Airoldi L, Armelle M, et al. White blood cell DNA adducts, smoking, and NAT2 and GSTM1 genotypes in bladder cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1998;7:341-6.